ALPN vs. PRGO, NUVL, MDGL, ALKS, BBIO, OGN, CBAY, RARE, INSM, and PBH
Should you be buying Alpine Immune Sciences stock or one of its competitors? The main competitors of Alpine Immune Sciences include Perrigo (PRGO), Nuvalent (NUVL), Madrigal Pharmaceuticals (MDGL), Alkermes (ALKS), BridgeBio Pharma (BBIO), Organon & Co. (OGN), CymaBay Therapeutics (CBAY), Ultragenyx Pharmaceutical (RARE), Insmed (INSM), and Prestige Consumer Healthcare (PBH). These companies are all part of the "pharmaceutical preparations" industry.
Perrigo (NYSE:PRGO) and Alpine Immune Sciences (NASDAQ:ALPN) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, valuation, dividends and community ranking.
Perrigo has a net margin of -0.27% compared to Perrigo's net margin of -54.66%. Alpine Immune Sciences' return on equity of 7.34% beat Perrigo's return on equity.
Perrigo received 383 more outperform votes than Alpine Immune Sciences when rated by MarketBeat users. Likewise, 66.78% of users gave Perrigo an outperform vote while only 64.57% of users gave Alpine Immune Sciences an outperform vote.
95.9% of Perrigo shares are owned by institutional investors. Comparatively, 75.2% of Alpine Immune Sciences shares are owned by institutional investors. 0.7% of Perrigo shares are owned by company insiders. Comparatively, 42.3% of Alpine Immune Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Perrigo has a beta of 0.63, meaning that its stock price is 37% less volatile than the S&P 500. Comparatively, Alpine Immune Sciences has a beta of 0.97, meaning that its stock price is 3% less volatile than the S&P 500.
Perrigo presently has a consensus target price of $40.67, indicating a potential upside of 24.02%. Alpine Immune Sciences has a consensus target price of $50.33, indicating a potential downside of 22.08%. Given Alpine Immune Sciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe Perrigo is more favorable than Alpine Immune Sciences.
Perrigo has higher revenue and earnings than Alpine Immune Sciences. Perrigo is trading at a lower price-to-earnings ratio than Alpine Immune Sciences, indicating that it is currently the more affordable of the two stocks.
In the previous week, Perrigo had 3 more articles in the media than Alpine Immune Sciences. MarketBeat recorded 8 mentions for Perrigo and 5 mentions for Alpine Immune Sciences. Perrigo's average media sentiment score of 0.82 beat Alpine Immune Sciences' score of 0.80 indicating that Alpine Immune Sciences is being referred to more favorably in the news media.
Summary
Perrigo beats Alpine Immune Sciences on 12 of the 17 factors compared between the two stocks.
Get Alpine Immune Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALPN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ALPN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Alpine Immune Sciences Competitors List
Related Companies and Tools
